About Astria Therapeutics
Astria Therapeutics is a company based in Boston (United States) founded in 2008 by Jill Milne was acquired by BioCryst in October 2025. It operates as a HealthTech. Astria Therapeutics has raised $196.54 million across 15 funding rounds from investors including BioCryst, HHS and Perceptive Advisors. The company has 78 employees as of December 31, 2024. Astria Therapeutics has completed 1 acquisition, including Quellis Biosciences. Astria Therapeutics offers products and services including Navenibart (STAR-0215) and STAR-0310. Astria Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others.
- Headquarter Boston, United States
- Employees 78 as on 31 Dec, 2024
- Founders Jill Milne
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Astria Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-94.26 M-29.32as on Dec 31, 2024
-
EBITDA
$-111.56 M-64.46as on Dec 31, 2024
-
Total Equity Funding
$196.54 M (USD)
in 15 rounds
-
Latest Funding Round
$110.01 M (USD), Post-IPO
Jan 29, 2021
-
Investors
BioCryst
& 4 more
-
Employee Count
78
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
BioCryst
(Oct 17, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Astria Therapeutics
Astria Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ATXS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Astria Therapeutics
Astria Therapeutics offers a comprehensive portfolio of products and services, including Navenibart (STAR-0215) and STAR-0310. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed for treating Hereditary Angioedema in patients.
Designed for managing Atopic Dermatitis in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Astria Therapeutics
Astria Therapeutics has successfully raised a total of $196.54M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $110.01 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Post-IPO — $110.0M
-
First Round
First Round
(02 Feb 2009)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - Astria Therapeutics | Valuation |
investors |
|
| Mar, 2015 | Amount | Series B - Astria Therapeutics | Valuation |
investors |
|
| Nov, 2013 | Amount | Series B - Astria Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Astria Therapeutics
Astria Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include BioCryst, HHS and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Astria Therapeutics
Astria Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Quellis Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody-based therapeutics for rare diseases are developed and optimized.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Astria Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Astria Therapeutics Comparisons
Competitors of Astria Therapeutics
Astria Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Biogen and Rhythm Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Astria Therapeutics
Frequently Asked Questions about Astria Therapeutics
When was Astria Therapeutics founded?
Astria Therapeutics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Astria Therapeutics located?
Astria Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Astria Therapeutics?
Jill Milne is the current CEO of Astria Therapeutics. They have also founded this company.
Is Astria Therapeutics a funded company?
Astria Therapeutics is a funded company, having raised a total of $196.54M across 15 funding rounds to date. The company's 1st funding round was a Series B of $32.43M, raised on Feb 02, 2009.
How many employees does Astria Therapeutics have?
As of Dec 31, 2024, the latest employee count at Astria Therapeutics is 78.
What does Astria Therapeutics do?
Astria Therapeutics is engaged in the development of life-changing therapies for patients and families affected by allergic and immunologic diseases. The company is dedicated to addressing unmet needs in therapeutic areas such as Hereditary Angioedema and Atopic Dermatitis. Solutions like Navenibart (STAR-0215) and STAR-0310 are being developed through clinical trials to provide innovative treatment options. The organization is guided by patient stories and community feedback to shape its scientific and therapeutic advancements. Sectors of focus include biotechnology and healthcare, with an emphasis on transparency and trust-building with stakeholders.
Who are the top competitors of Astria Therapeutics?
Astria Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Astria Therapeutics offer?
Astria Therapeutics offers Navenibart (STAR-0215) and STAR-0310.
Is Astria Therapeutics publicly traded?
Yes, Astria Therapeutics is publicly traded on NASDAQ under the ticker symbol ATXS.
How many acquisitions has Astria Therapeutics made?
Astria Therapeutics has made 1 acquisition, including Quellis Biosciences.
Who are Astria Therapeutics's investors?
Astria Therapeutics has 5 investors. Key investors include BioCryst, HHS, Perceptive Advisors, Lightstone Ventures, and MedImmune Ventures.
What is Astria Therapeutics's ticker symbol?
The ticker symbol of Astria Therapeutics is ATXS on NASDAQ.